Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the opening of its expanded non-commercial specialty pharmacy, FortreaRx™, located in Lake Mary,
Tharimmune’s Oral ‘Under The Cheek’ Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
February 20, 5:10 PM
Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential for liver-related conditions.
February 20, 4:50 PM
Helldivers 2, a third-person shooter game funded by Sony Group Corp. (NYSE: SONY), achieved an impressive milestone with 409,337 concurrent players on Valve's Steam over the weekend, making it the fifth most popular game on the platform.
February 20, 4:38 PM
Elon Musk's SpaceX is gaining ground as a major defense contractor, strengthening its ties with military and intelligence agencies, according to the Wall Street Journal.
Tech’s Moment Of Truth: Why Josh Brown Says The Reaction Is What Matters When Nvidia Reports Q4 Earnings
February 20, 4:37 PM
Nvidia Corp is due to report earnings this week and Ritholtz Wealth Management's Josh Brown believes the reaction to the print could have massive consequences for the markets.
ARS Pharma Readies Data In Response To FDA’s Rejection For Its EpiPen Alternative For Severe Allergic Reactions
February 20, 3:53 PM
NAC study results by ARS Pharma comparing neffy (epinephrine nasal spray) to intramuscular injection. Data submission is expected in Q2 2024.
What’s In Store For Block’s Q4 Earnings? Analysts Spotlight On CEO Jack Dorsey’s Actions To Boost Square’s GPV Growth
February 20, 3:29 PM
Analyst spotlight on CEO Jack Dorsey's strategies to boost Square's GPV growth ahead of Block's Q4 earnings release.
February 20, 3:28 PM
The latest update from Xbox Wire outlines the new additions to Xbox Game Pass for the end of February and the beginning of March 2024. Seven titles are joining the service, including:
February 20, 2:43 PM
Cannabis Stocks have been trending downward for two weeks, but the MJUS ETF rebalancing efforts gave some of them an additional shove.
Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report
February 20, 2:24 PM
Teva Pharmaceutical Industries confirms unity and dispels split rumors. CEO Richard Francis emphasizes the synergy between generics and branded drugs.